14,169 reports of this reaction
1.9% of all ACETAMINOPHEN TABLET EXTENDED RELEASE reports
#8 most reported adverse reaction
DYSPNOEA is the #8 most commonly reported adverse reaction for ACETAMINOPHEN TABLET EXTENDED RELEASE, manufactured by AAA Pharmaceutical, Inc.. There are 14,169 FDA adverse event reports linking ACETAMINOPHEN TABLET EXTENDED RELEASE to DYSPNOEA. This represents approximately 1.9% of all 733,850 adverse event reports for this drug.
Patients taking ACETAMINOPHEN TABLET EXTENDED RELEASE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ACETAMINOPHEN TABLET EXTENDED RELEASE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ACETAMINOPHEN TABLET EXTENDED RELEASE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 14,169 FDA reports for ACETAMINOPHEN TABLET EXTENDED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.9% of all adverse event reports for ACETAMINOPHEN TABLET EXTENDED RELEASE, making it a notable side effect.
If you experience dyspnoea while taking ACETAMINOPHEN TABLET EXTENDED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.